PMLiVE | Pharmaceutical industry news, articles, jobs, reports, …
WEBBayer presents positive results for Kerendia in late-stage heart failure study. Eli Lilly and HAYA Therapeutics enter metabolic condition partnership worth $1bn. Bayer and NextRNA Therapeutics enter oncology partnership worth $547m. J&J to expand cardiovascular capabilities with V-Wave acquisition worth up to $1.7bn.
Novartis restructures organisation to support growth and …
WEBApr 4, 2022 · Novartis has revealed its plans for the launch of a new organisational structure and operating model designed to support its innovation, growth, and product development goals as a focused medicines organisation over the next ten years. Key to the restructure is the integration of the pharmaceuticals and oncology business units, which will be ...
Enzyvant and Altavant announce merger to accelerate rare disease ...
WEBDec 8, 2022 · Enzyvant Therapeutics (Enzyvant) and Altavant Sciences (Altavant) have announced a merger to form a biopharmaceutical company focused on accelerating the development of therapies for patients with rare diseases. The combined company, which retains the name Enzyvant, will have a full range of …
AbbVie’s Rinvoq has ‘marginal clinical benefit’ over ... - PMLiVE
WEBNov 27, 2019 · According to ICER, this evidence demonstrates that Rinvoq provides a small to substantial health benenfit over Humira. The institute found that compared to the TNF blocker, Rinvoq’s value-based price benchmark is between $44,000 to $45,000 per year of treatment. This is a significant change from its initial cost-effectiveness threshold.
This month in 1989: the creation of Bristol-Myers Squibb
WEBJul 29, 2014 · So far this year the pharma industry has not been short of speculation on potential mergers between some of the world’s biggest companies. The main story of interest has, of course, been Pfizer’s failed bid for AstraZeneca, although Valeant’s pursuit of Allergan and AbbVie’s attempts to take over Shire have also been consistently in …
AZ showcases data for next-generation PARP inhibitor AZD5305
WEBApr 12, 2021 · Data for AZD5305 will demonstrate how the next wave of DNA damage response medicines can build on the success of PARP inhibitors, potentially allowing patients to stay on treatment longer,”said Susan Galbraith, senior vice president and head of research and early development, oncology R&D at …
Roche signs biologics partnership with Samsung - PMLiVE
WEBOct 24, 2013 · Swiss pharma company Roche has signed a biologics manufacturing deal with Samsung BioLogics. The long-term agreement will see Samsung produce Roche biologics at its two facilities in Incheon, South Korea, one of which is still under construction. The deal comes one week after Roche outlined its …
PME - PMLiVE
WEBPharmaceutical Market Europe – October 2023. Launch excellence – adapting to data disruption; preparing for the clinical trials of the future; the impact of cell therapies on cancer treatments.
Astellas’ Xospata scores positive CHMP recommendation
WEBSep 23, 2019 · Japanese pharma Astellas has won a positive recommendation from the EMA’s Committee for Medical Products for Human Use (CHMP) for Xospata (gilteritinib), setting up a likely approval in the EU in the near future. The FLT3 inhibitor received the positive opinion for use as a monotherapy in the treatment of …
Novartis and GSK complete oncology and vaccines swap
WEBMar 2, 2015 · Under the terms of the deal GSK is paying $5.25bn in case for Novartis’ vaccines business while Novartis is stumping up $16bn for GSK’s oncology business. The two companies are also pooling their resources in consumer health, creating a joint venture that will be 63.5% owned by GSK. Details of the asset swap were first revealed last April.